80 results about "Tissue ischemia" patented technology

This invention relates to methods of reducing the damaging effect of an injury to mammalian cells by treatment with compounds which reduce cell death or dysfunction, including cellular damage following episodes of tissue ischemia, trauma, epilepsy, and acute or chronic degeneration. The invention discloses methods of treating these disorders by administering inhibitors that disrupt protein-protein interactions involved in these disorders, screening methods to identify such inhibitors and specific compositions useful for treating these disorders.

A compound of the formula wherein R1 is: R5 is: and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly, myocardial ischemia.

The present inventors have developed a novel composition and method for inhibiting inflammation and treating of symptoms of tissue ischemia, including that associated with peripheral and cardiac vascular disease by local administration of a pharmaceutical composition including an effective amount of a poloxamer.

This invention relates to methods of reducing the damaging effect of an injury to mammalian cells by treatment with compounds which reduce cell death or dysfunction, including cellular damage following episodes of tissue ischemia, trauma, epilepsy, and acute or chronic degeneration. The invention discloses methods of treating these disorders by administering inhibitors that disrupt protein-protein interactions involved in these disorders, screening methods to identify such inhibitors and specific compositions useful for treating these disorders.

An implantable ischemia detection system in which a white LED (105) produces a continuous, visible, broadband light illuminating a target site (125). Light backscattered by the target is collected by a sensor (155), allowing for an index of ischemia to be determined, and subsequently transmitted by a sending unit (167). Power is provided by an internal power source (179). The entire implantable device is encapsulated by a biocompatible shell (102) to add long-term safety with regard to implantation.

An implantable ischemia detection device in which a broadband light source produces a continuous, visible, broadband light illuminating capillary sites within a well localized target tissue is provided. Light backscattered by the target tissue is collected by a sensor, allowing for an index of ischemia to be determined, and subsequently transmitted by a sending unit. Optionally, the device may be provided with an internal power source, the entire device encapsulated by a biocompatible shell to add long-term safety while implanted at a target tissue site.

Methods and devices are provided for the local delivery of anti-ischemic agents which reduce myocardial tissue damage due to ischemia or reperfusion, in combination with compounds that sensitize the response of the tissue to the anti-ischemic agent. The therapeutic agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the tissue.

An implantable ischemia detection system in which a white LED (105) produces a continuous, visible, broadband light illuminating a target site (125). Light backscattered by the target is collected by a sensor (155), allowing for an index of ischemia to be determined, and subsequently transmitted by a sending unit (167). Power is provided by an internal power source (179). The entire implantable device is encapsulated by a biocompatible shell (102) to add long-term safety with regard to implantation.

A3 agonists, methods of using such A3 agonists and pharmaceutical compositions containing such A3 agonists. The A3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

Provided herein are compositions and methods for preventing, ameliorating, and / or reducing tissue ischemia and / or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and / or blocking TSP1 and / or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. This in turn reduces or prevents tissue necrosis and death. The therapeutics identified herein allow for precise regulation of blood flow to tissues and organs which need it, while substantially avoiding systemic complications. Methods and compositions described herein can be used to increase tissue survival under conditions of trauma and surgery, as well as conditions of chronic vascular disease. Also disclosed are methods for the treatment of elderly subjects using agents that affect TSP1 and CD47 and thereby affect tissue perfusion. Additionally, provided herein are compositions and methods for influencing blood coagulation, allowing for controlled increased or decreased blood clotting. Additionally, provided herein are compositions and methods for decreasing blood flow, as in the case of cancer through mimicking the effects of TSP1 and CD47 on blood vessel diameter and blood flow.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia.

Fusion proteins comprising a single chain antigen-binding domain (scFv) of a monoclonal antibody, linked to an anti-thrombotic agent, anti-inflammatory agent, or a pro-drug thereof are provided, where the polypeptide binds to a binding site (antigen) expressed on the surface of a red blood cell at a density greater than 5,000 copies per red blood cell. Pharmaceutical compositions comprising these fusion proteins, and methods of delivering an anti-thrombotic agent to the surface of a red blood cell via delivery of these fusion proteins, and methods of treating or preventing thrombosis, tissue ischemia, acute myocardial infarction (AMI), ischemic stroke, cerebrovascular disease, pulmonary embolism, or ischemic peripheral vascular disease via administration of the fusion proteins or compositions comprising same are also provided.

Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal with low doses of pyridoxine, pyridoxal-5′phosphate, pyridoxal or pyridoxamine. Compositions and kits for said method is also included.

The present invention discloses one kind of stem cell preparation for treating tissue ischemia disease and its preparation process. The stem cell preparation includes mononuclear cell separated and extracted form peripheral blood, CD 133+ cell separated and extracted from other body's tissue, or vascular endothelial ancestral cell derived from CD133+cell. The preparation process includes separation and purification of stem cell, culture, preparation of cell suspension and other steps. The positive effect of the present invention is that the stem cell preparation has high curative effect and no toxic side effect to obliterative cardiac, cerebral and peripheral vascular and corresponding genetic defective diseases.

A molded plastic spine board having specialized padding strategically located in the board and stiffing members. The specialized padding reduces patient discomfort and aids perfusion in the regions that are in contact with the board while the patient is immobilized on the board thereby helping to prevent tissue ischemia and pressure ulcer formation. The stiffening members strengthen the board eliminating deflection of the board thereby keeping the patient immobilized while eliminating artifacts (shadows and interference) in x-rays thereby ensuring good x-ray examination.

The present invention generally provides methods for preventing or treating tissue ischemia using CXCR4 antagonists. In one embodiment, the methods include administering to a mammal a therapeutically effective amount of a particular bicylic polyamine to elevate peripheral blood EPCs. The invention has a wide spectrum of applications including reducing or eliminating tissue ishemica associated with a myocardial infarct (heart attack).

The present invention generally provides methods for preventing, treating or reducing the severity of symptoms associated with tissue ischemia by administering a CXCR4 antagonist in combination with at least one nucleic acid encoding a morphogen or effective fragment thereof. In one embodiment, the methods include elevating peripheral blood endothelial progenitor cells (EPCs), bone marrow-derived stem cells (BMSCs), or both cell types. The invention has a wide spectrum of applications including reducing or eliminating tissue ischemia, especially tissue ischemia associated with a myocardial infarct (heart attack).

The invention relates to a wrist joint movable connecting rod for fixing across a wrist joint, which comprises a metacarpal bone movable seat (2), a radius movable seat (2'), a metacarpal bone connecting rod (1) fixed on the metacarpal bone movable seat (2), a radius connecting rod (9) connected with the radius movable seat (2') and an elasticity-adjustable locking bolt (4) connecting the metacarpal bone movable seat (2) and the radius movable seat (2'). The wrist joint movable connecting rod for fixing across the wrist joint overcomes the defect that: when the surrounding of the wrist joint fractures, the conventional fixation of the wrist joint can cause blood supply obstacles and tissue ischemia and hypoxia of wrist joint surrounding tissues and further cause the disuse change of joint capsules, ligaments, joint surrounding tissues and bones. The wrist joint movable connecting rod for fixing across the wrist joint can bring function exercise to the wrist joint earlier without affecting the fixation and the recovery of the fracture.

NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue.

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and / or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).

The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.

The invention provides a dynamic physical examination method and an automatic corporeity evaluation system. The dynamic physical examination method includes two modes: 1) measuring blood oxygen, blood pressure and heart rhythm by enabling a person to hold breath; 2) measuring the blood oxygen, the blood pressure and the heart rhythm by enabling the person to continuously squat. Normal value of a static examination is used as a reference base line of a dynamic physical examination performed by using the dynamic physical examination method, and therefore heart and lung functions and a circulatory system of the person under pressure are evaluated. A breath holding examination aims at examining high value of the blood pressure and heart rhythm changes under the circumstance of organ tissue ischemia, and a continuous squatting examination aims at examining high value of the heart rhythm and blood pressure changes under the circumstance of exercise. The automatic corporeity evaluation system analyzes corporeity and potential disease risk of the person by combining dynamic physical sign measurement value with static physical examination normal value and using front end embedded software and background big data cloud computing. Then, corresponding health advice and corresponding medical service recommendation are provided.

The invention discloses a balloon dilatation catheter. The balloon dilatation catheter comprises a soft head, a balloon, an inner tube, a far-end outer tube, a transition tube, a hypotube and a catheter handle, wherein a combination body of the soft head and the inner tube is placed in and connected to the far-end neck part of the balloon; the inner tube penetrates through an inner cavity of the far-end outer tube and an inner cavity of the balloon; the farthest end of the far-end outer tube is placed in the near-end neck part of the balloon and is connected with the near-end neck part of theballoon; one or more blood flow guide grooves are formed in the surface of the balloon in the axial direction; and the inner tube is of a multi-layer structure, an outer layer is a macromolecule layerwith gradually changing hardness, a middle layer is a metal net, and an inner layer is PTFE. The balloon is provided with the blood flow guide grooves, so that blood flow cannot be completely blockedwhen the balloon is filled, and damage caused by ischemia of far-end blood vessels and tissue is avoided. The far ends of the balloon and the catheter are very smooth, and the balloon dilatation catheter is good in control performance and high in penetrating through performance, so that the surgery is quick, the cost is saved, and the risk to a patient is low.

Compounds of formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia, e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2−). The pharmaceutical compositions of the invention are useful, for example, for the treatment of chronic tissue ischemia, in particular peripheral artery disease (PAD).